Troy Cox, Michael Pellini

Foundation Medicine announced that it has appointed Troy Cox as CEO to succeed Michael Pellini, who has been appointed as chairman of the board of directors. Pellini replaces Alexis Borisy, who will continue to serve on the board. Cox joins Foundation Medicine from Roche-Genentech, where he led one of the largest oncology portfolios in the US. Before joining Genentech, he held leadership positions at UCB BioPharma, Sanofi-Aventis, and Schering-Plough.


Philip Bourne

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.